脂蛋白(a)的清除仍是未解之谜。
Lipoprotein(a) Removal Still a Mystery.
机构信息
1 Baker Heart & Diabetes Institute Melbourne Australia.
出版信息
J Am Heart Assoc. 2019 Feb 19;8(4):e011903. doi: 10.1161/JAHA.118.011903.
Abstract
See Article by Shapiro et al.
摘要
见 Shapiro 等人的文章。
相似文献
1
Lipoprotein(a) Removal Still a Mystery.脂蛋白(a)的清除仍是未解之谜。
J Am Heart Assoc. 2019 Feb 19;8(4):e011903. doi: 10.1161/JAHA.118.011903.
2
From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.从脂蛋白吸附术到前蛋白转化酶枯草溶菌素 9 抑制剂：对心血管疾病患者的低密度脂蛋白胆固醇和 C 反应蛋白水平的影响。
Eur J Prev Cardiol. 2018 Nov;25(17):1843-1851. doi: 10.1177/2047487318792626. Epub 2018 Jul 30.
3
Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9.低密度脂蛋白胆固醇和脂蛋白(a)水平对靶向枯草溶菌素/kexin 9型前蛋白转化酶的单克隆抗体的不一致反应。
J Clin Lipidol. 2017 May-Jun;11(3):667-673. doi: 10.1016/j.jacl.2017.03.001. Epub 2017 Mar 9.
4
Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors.脂蛋白(a)与前蛋白转化酶枯草溶菌素/kexin 9型抑制剂
Clin Res Cardiol Suppl. 2019 Apr;14(Suppl 1):45-50. doi: 10.1007/s11789-019-00099-z.
5
AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.AMG145，一种针对前蛋白转化酶枯草溶菌素 9 的单克隆抗体，可显著降低接受他汀类药物治疗的高胆固醇血症患者的脂蛋白(a)：来自 LDL-C 评估与前蛋白转化酶枯草溶菌素 9 单克隆抗体抑制联合他汀类药物治疗（LAPLACE）-心肌梗死溶栓治疗（TIMI）57 试验的分析。
Circulation. 2013 Aug 27;128(9):962-9. doi: 10.1161/CIRCULATIONAHA.113.001969. Epub 2013 Jul 24.
6
Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.前蛋白转化酶枯草溶菌素 9 抑制：降低心血管疾病风险的新治疗机制。
Circulation. 2015 Oct 27;132(17):1648-66. doi: 10.1161/CIRCULATIONAHA.115.016080.
7
Clinical guidance on the contemporary use of proprotein convertase subtilisin/kexin type 9 monoclonal antibodies.关于前蛋白转化酶枯草溶菌素 9 单克隆抗体的当代应用的临床指导。
Diabetes Obes Metab. 2019 Apr;21 Suppl 1:52-62. doi: 10.1111/dom.13637.
8
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects.抑制前蛋白转化酶枯草溶菌素 9（PCSK9）用玻卡鲁胺对高胆固醇血症患者脂蛋白颗粒的影响。
Clin Ther. 2017 Nov;39(11):2243-2259.e5. doi: 10.1016/j.clinthera.2017.09.009. Epub 2017 Oct 14.
9
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.前蛋白转化酶枯草溶菌素/克新9型（PCSK9）抑制剂：当前观点与未来展望。
Nutr Metab Cardiovasc Dis. 2016 Oct;26(10):853-62. doi: 10.1016/j.numecd.2016.05.006. Epub 2016 May 30.
10
Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment.尽管前蛋白转化酶枯草溶菌素 9 抗体治疗可强力降低低密度脂蛋白胆固醇，但脂蛋白(a)升高的患者仍存在持续性动脉壁炎症。
Eur Heart J. 2019 Sep 1;40(33):2775-2781. doi: 10.1093/eurheartj/ehy862.
引用本文的文献
1
Interaction Between Lipoprotein(a) and Other Lipid Molecules: A Review of the Current Literature.脂蛋白(a)与其他脂质分子之间的相互作用：当前文献综述
Biomolecules. 2025 Jan 22;15(2):162. doi: 10.3390/biom15020162.
2
Comprehensive Investigation of Circulating Biomarkers and Their Causal Role in Atherosclerosis-Related Risk Factors and Clinical Events.全面研究循环生物标志物及其在动脉粥样硬化相关风险因素和临床事件中的因果作用。
Circ Genom Precis Med. 2020 Dec;13(6):e002996. doi: 10.1161/CIRCGEN.120.002996. Epub 2020 Oct 30.
3
Molecular, Population, and Clinical Aspects of Lipoprotein(a): A Bridge Too Far?脂蛋白(a)的分子、群体和临床方面：跨度太大？
J Clin Med. 2019 Nov 27;8(12):2073. doi: 10.3390/jcm8122073.
本文引用的文献
1
Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab.依洛尤单抗降低 PCSK9 治疗后 LDL-C 与脂蛋白(a)的关系。
J Am Heart Assoc. 2019 Feb 19;8(4):e010932. doi: 10.1161/JAHA.118.010932.
2
Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials.基线和他汀治疗时脂蛋白(a)水平对心血管事件的预测作用：他汀类药物疗效试验的个体患者数据分析荟萃分析。
Lancet. 2018 Oct 13;392(10155):1311-1320. doi: 10.1016/S0140-6736(18)31652-0. Epub 2018 Oct 4.
3
Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis.载脂蛋白 LPA 变异与冠心病风险的关联及对脂蛋白(a)降低治疗的意义：一项孟德尔随机分析。
JAMA Cardiol. 2018 Jul 1;3(7):619-627. doi: 10.1001/jamacardio.2018.1470.
4
Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1.靶向 PCSK9 的 siRNA 治疗对动脉粥样硬化脂蛋白的影响：ORION 1 的预先指定次要终点。
Circulation. 2018 Sep 25;138(13):1304-1316. doi: 10.1161/CIRCULATIONAHA.118.034710.
5
LPA Variants Are Associated With Residual Cardiovascular Risk in Patients Receiving Statins.载脂蛋白 LPA 变异与接受他汀类药物治疗的患者的残余心血管风险相关。
Circulation. 2018 Oct 23;138(17):1839-1849. doi: 10.1161/CIRCULATIONAHA.117.031356.
6
Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk.阿托伐他汀、胆固醇酯转移蛋白抑制和糖尿病对高心血管风险患者循环前蛋白枯草溶菌素 9 和脂蛋白(a)水平的影响。
J Clin Lipidol. 2018 Jan-Feb;12(1):130-136. doi: 10.1016/j.jacl.2017.10.001. Epub 2017 Oct 12.
7
Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium.脂蛋白(a)与欧洲人群心血管疾病风险：来自 BiomarCaRE 联盟的研究结果。
Eur Heart J. 2017 Aug 21;38(32):2490-2498. doi: 10.1093/eurheartj/ehx166.
8
Significance of lipoprotein(a) levels in familial hypercholesterolemia and coronary artery disease.脂蛋白(a)水平在家族性高胆固醇血症和冠状动脉疾病中的意义。
Atherosclerosis. 2017 May;260:67-74. doi: 10.1016/j.atherosclerosis.2017.03.021. Epub 2017 Mar 18.
9
A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies.在语境中检验：脂蛋白(a)：诊断、预后、争议和新兴疗法。
J Am Coll Cardiol. 2017 Feb 14;69(6):692-711. doi: 10.1016/j.jacc.2016.11.042.
10
Phenotypic Characterization of Genetically Lowered Human Lipoprotein(a) Levels.遗传性降低的人脂蛋白(a)水平的表型特征
J Am Coll Cardiol. 2016 Dec 27;68(25):2761-2772. doi: 10.1016/j.jacc.2016.10.033.
Zotero 插件